Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mu Sun

Showing results (271-280 of 338) with videos related to

Pageof 34
Sort By:
Cancer|June 26, 2020
Biomarker-driven phase 2 umbrella trial study for patients with recurrent small cell lung cancer failing platinum-based chemotherapySehhoon Park, Joonho Shim, Peter G S Mortimer, et al.
European Journal of Immunology|June 9, 2020
MDSC subtypes and CD39 expression on CD8<sup>+</sup> T cells predict the efficacy of anti-PD-1 immunotherapy in patients with advanced NSCLCJiae Koh, Youjin Kim, Kyoung Young Lee, et al.
Cancer Research and Treatment|January 6, 2017
Genetic Alterations and Their Clinical Implications in High-Recurrence Risk Papillary Thyroid CancerMin-Young Lee, Bo Mi Ku, Hae Su Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 12, 2019
Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09)Jang Ho Cho, Sung Hee Lim, Ho Jung An, et al.
Lung Cancer (Amsterdam, Netherlands)|March 26, 2013
Clinical applicability of staging small cell lung cancer according to the seventh edition of the TNM staging systemByung Woo Jhun, Kyung-Jong Lee, Kyeongman Jeon, et al.
Cancer|October 16, 2023
Biomarker-driven phase 2 umbrella trial: Clinical efficacy of olaparib monotherapy and combination with ceralasertib (AZD6738) in small cell lung cancerSehhoon Park, Yu Jung Kim, Young Joo Min, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 1, 2017
Randomized Phase II Trial Comparing Chemoradiotherapy with Chemotherapy for Completely Resected Unsuspected N2-Positive Non-Small Cell Lung CancerJong-Mu Sun, Jae Myung Noh, Dongryul Oh, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 28, 2022
A Phase 2 Study of Palbociclib for Recurrent or Refractory Advanced Thymic Epithelial Tumors (KCSG LU17-21)Hyun Ae Jung, Miso Kim, Hae Su Kim, et al.
European Journal of Cancer (Oxford, England : 1990)|July 17, 2012
A prospective multicentre phase II study of cisplatin and weekly docetaxel as first-line treatment for recurrent or metastatic nasopharyngeal cancer (KCSG HN07-01)Jun Ho Ji, , Tak Yun, et al.
Lung Cancer (Amsterdam, Netherlands)|November 7, 2025
Phase II study of lazertinib and pemetrexed in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer with leptomeningeal metastases: the KCSG LU 21-01, LAZARUS studyHyun Ae Jung, Tae Min Kim, Hye Ryun Kim, et al.
Pageof 34

Showing results (271-280 of 338) with videos related to

Sort By:
Pageof 34
Cancer|June 26, 2020
Biomarker-driven phase 2 umbrella trial study for patients with recurrent small cell lung cancer failing platinum-based chemotherapySehhoon Park, Joonho Shim, Peter G S Mortimer, et al.
European Journal of Immunology|June 9, 2020
MDSC subtypes and CD39 expression on CD8<sup>+</sup> T cells predict the efficacy of anti-PD-1 immunotherapy in patients with advanced NSCLCJiae Koh, Youjin Kim, Kyoung Young Lee, et al.
Cancer Research and Treatment|January 6, 2017
Genetic Alterations and Their Clinical Implications in High-Recurrence Risk Papillary Thyroid CancerMin-Young Lee, Bo Mi Ku, Hae Su Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 12, 2019
Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09)Jang Ho Cho, Sung Hee Lim, Ho Jung An, et al.
Lung Cancer (Amsterdam, Netherlands)|March 26, 2013
Clinical applicability of staging small cell lung cancer according to the seventh edition of the TNM staging systemByung Woo Jhun, Kyung-Jong Lee, Kyeongman Jeon, et al.
Cancer|October 16, 2023
Biomarker-driven phase 2 umbrella trial: Clinical efficacy of olaparib monotherapy and combination with ceralasertib (AZD6738) in small cell lung cancerSehhoon Park, Yu Jung Kim, Young Joo Min, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 1, 2017
Randomized Phase II Trial Comparing Chemoradiotherapy with Chemotherapy for Completely Resected Unsuspected N2-Positive Non-Small Cell Lung CancerJong-Mu Sun, Jae Myung Noh, Dongryul Oh, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 28, 2022
A Phase 2 Study of Palbociclib for Recurrent or Refractory Advanced Thymic Epithelial Tumors (KCSG LU17-21)Hyun Ae Jung, Miso Kim, Hae Su Kim, et al.
European Journal of Cancer (Oxford, England : 1990)|July 17, 2012
A prospective multicentre phase II study of cisplatin and weekly docetaxel as first-line treatment for recurrent or metastatic nasopharyngeal cancer (KCSG HN07-01)Jun Ho Ji, , Tak Yun, et al.
Lung Cancer (Amsterdam, Netherlands)|November 7, 2025
Phase II study of lazertinib and pemetrexed in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer with leptomeningeal metastases: the KCSG LU 21-01, LAZARUS studyHyun Ae Jung, Tae Min Kim, Hye Ryun Kim, et al.
Pageof 34